Lidopro

Capsaicin, Lidocaine, Menthol, And Methyl Salicylate


Medsource Pharmaceuticals
Human Otc Drug
NDC 45865-897
Lidopro also known as Capsaicin, Lidocaine, Menthol, And Methyl Salicylate is a human otc drug labeled by 'Medsource Pharmaceuticals'. National Drug Code (NDC) number for Lidopro is 45865-897. This drug is available in dosage form of Ointment. The names of the active, medicinal ingredients in Lidopro drug includes Capsaicin - .000325 g/g Lidocaine Hydrochloride - .04 g/g Menthol - .1 g/g Methyl Salicylate - .275 g/g . The currest status of Lidopro drug is Active.

Drug Information:

Drug NDC: 45865-897
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Lidopro
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Capsaicin, Lidocaine, Menthol, And Methyl Salicylate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Medsource Pharmaceuticals
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Ointment
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAPSAICIN - .000325 g/g
LIDOCAINE HYDROCHLORIDE - .04 g/g
MENTHOL - .1 g/g
METHYL SALICYLATE - .275 g/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 04 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:medsource pharmaceuticals
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1601095
1601097
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UNII:S07O44R1ZM
V13007Z41A
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Amide Local Anesthetic [EPC]
Amides [CS]
Antiarrhythmic [EPC]
Local Anesthesia [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
45865-897-01121 g in 1 BOTTLE (45865-897-01)01 Jun, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic

Purpose topical analgesic

Purpose topical analgesic

Purpose topical analgesic

Product Elements:

Lidopro capsaicin, lidocaine, menthol, and methyl salicylate allantoin aloe vera leaf ammonium acryloyldimethyltaurate/vp copolymer cetyl alcohol chamomile dimethicone edetate disodium ethylhexylglycerin glycerin glyceryl monostearate peg-100 stearate trolamine water capsaicin capsaicin lidocaine hydrochloride lidocaine lidocaine hydrochloride anhydrous menthol menthol methyl salicylate salicylic acid

Indications and Usage:

Uses : temporarily relieves minor aches and muscles pains associated with: arthritis simple back pain strains muscle soreness

Warnings:

Warnings for external use only do not use on open wounds, cuts, damaged or infected skin with bandage or a heating pad if condition worsens or symptoms persists for more than 7 days excessive skin irritation occurs ask a doctor before use if you are allergic to any ingredients, paba, aspirin products or sulfa when using this product avoid contact with eyes, genitals, and other mucus membranes. if eye contact occurs, rinse thoroughly with water. if pregnant or breast feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away. package not child resistant. store a t 20 ○ c - 25 ○ c (68 ○ f - 77 ○ f)

Do Not Use:

Warnings for external use only do not use on open wounds, cuts, damaged or infected skin with bandage or a heating pad if condition worsens or symptoms persists for more than 7 days excessive skin irritation occurs ask a doctor before use if you are allergic to any ingredients, paba, aspirin products or sulfa when using this product avoid contact with eyes, genitals, and other mucus membranes. if eye contact occurs, rinse thoroughly with water. if pregnant or breast feeding, ask a health professional before use. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away. package not child resistant. store a t 20 ○ c - 25 ○ c (68 ○ f - 77 ○ f)

When Using:

When using this product avoid contact with eyes, genitals, and other mucus membranes. if eye contact occurs, rinse thoroughly with water.

Dosage and Administration:

Directions ad ults 18 years and children 12 years and older: apply product directly to affected area product may be used as necessary, but should not be used more than four times per day. wash hands immediately afterwards children 12 years or younger: ask a doctor

Package Label Principal Display Panel:

Principal display panel pdp

Further Questions:

For questions or comments please email info@terrainrx.com manufactured for terrain pharmaceuticals reno, nv 89501 made in the u.s.a. patent pending


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.